Description
Indication & Scope
Hympavzi® Marstacimab Injection provides routine prophylaxis to reduce bleeding frequency in patients with hemophilia A or B aged 12 years and older weighing ≥35 kg.
- Mechanism: Fully human IgG1 monoclonal antibody that specifically binds tissue factor pathway inhibitor (TFPI). It blocks TFPI’s endogenous anticoagulant activity, restores physiological blood coagulation cascade and reduces spontaneous bleeding events without factor replacement.
- Drug class: Anti-TFPI monoclonal antibody / Hemophilia prophylactic biological agent.
- Clinical use: Long-term preventive treatment for adolescents and adults with hemophilia A/B, with or without clotting factor inhibitors, to lower annualized bleeding rate.
| Generic Name | Marstacimab Injection |
| Brand Name | Hympavzi |
| Ingredient | Marstacimab |
| Dosage Form | Injection |
| Package | 150mg(1ml)*1 syringe/box |
| Conditions Treated | Hemophilia A and Hemophilia B |
| Taboos | Known severe hypersensitivity to marstacimab or any antibody formulation excipients; patients with active unmanaged thromboembolic disorders |
| Place of origin | Rijksweg 12, Puurs-Sint-Amands 2870 BELGIUM |
| Prescription type | Prescription-only |
| Storage Conditions | Sealed prefilled syringes refrigerated at 2°C to 8°C, do not freeze; avoid direct intense light exposure. |
| Manufacturer | Pfizer Inc. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | SJ20250026 |
| Approval Date | Nov 18, 2025 |
| Shelf Life | 30 months |
How to use ?
Recommended Dose: Loading dose: 300 mg subcutaneous split into two 150 mg injections on day 1; maintenance dose 150 mg once weekly starting 7 days after loading injection.
Time: Weekly subcutaneous injection, fixed same day each week, no meal restriction on timing.
Instructions for use: Inject subcutaneously at separate abdominal or thigh sites for loading dose two injections; rotate injection locations weekly; adjust to 300 mg weekly if bleeding control remains insufficient.
Interaction: Concurrent activated prothrombin complex concentrates raise thrombotic risk; monitor coagulation markers when combined with bypassing agents for breakthrough bleeds.
Side effects:
1. Common: injection site pruritus, headache, mild fever, joint pain, diarrhea, skin rash.
2.Severe rare adverse events: venous or arterial thrombosis, hypersensitivity anaphylaxis.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What coagulation protein target does Marstacimab Injection bind to?
It binds tissue factor pathway inhibitor (TFPI) to restore clotting function.
What is the standard maintenance dosing frequency for Marstacimab Injection?
150 mg administered subcutaneously once every week.
What severe adverse risk requires close clinical monitoring during treatment of Marstacimab Injection?
Increased risk of blood clotting and thromboembolic events.
Which patients are not allowed to receive Marstacimab Injection?
Patients with severe allergy to marstacimab or active untreated thrombosis.
Hympavzi® | Marstacimab Injection | Hemophilia | DengYueRX
INN: Marstacimab Injection
Indications: Hemophilia
Dosage Form: Injection
Strength: 150mg(1ml)/syringe
